Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Acne Vulgaris Medication

  • Author: Jaggi Rao, MD, FRCPC; Chief Editor: William D James, MD  more...
 
Updated: May 20, 2016
 

Medication Summary

The following information primarily pertains to the treatment of Propionibacterium acne vulgaris.

Antibiotics used to treat anaerobic infections usually suffice for other types of Propionibacterium infections. These include the penicillins, carbapenems, and clindamycin. In addition, vancomycin and teicoplanin (investigational) have been used. Some of these antibiotics are discussed after the treatment of acne vulgaris. Daptomycin has been used for the treatment of Propionibacterium osteomyelitis.[29]

Next

Retinoid-like Agents

Class Summary

These agents stimulate cellular retinoid receptors and help normalize keratinocyte differentiation and are comedolytic. In addition, they have anti-inflammatory properties. Oral isotretinoin also reduces sebum production in the skin. Retinoids are classified into 3 generations. The first comprises topical tretinoin and systemic isotretinoin. Acitretin is a second-generation retinoid used to treat psoriasis. The third-generation retinoids include topical adapalene tazarotene.

Topical tretinoin (Retin-A Micro, Atralin, Avita, Tretin-X, Renova)

 

Topical tretinoin inhibits microcomedo formation. It decreases cohesiveness of keratinocyesin sebaceous follicles, which allows for easy removal. It has anti-inflammatory properties. Topical tretinoin is available as a cream or gel.

Adapalene (Differin)

 

Adapalene inhibits microcomedo formation. It decreases cohesiveness of keratinocyesin sebaceous follicles, which allows for easy removal. It has anti-inflammatory properties. Adapalene is available as a cream, lotion, or gel.

Tazarotene (Tazorac, Fabior, Avage)

 

Tazarotene inhibits microcomedo formation. It decreases cohesiveness of keratinocyesin sebaceous follicles, which allows for easy removal. It has anti-inflammatory and immunological properties. Tazarotene is available as a cream or gel.

Isotretinoin (Claravis, Amnesteem, Absorica, Zenatane)

 

Isotretinoin is an oral retinoid indicated for recalcitrant, nodulocystic acne. It addresses all four pathogenic factors involved in the development of acne: follicular hyperkeratinization, inflammation, sebum production, and Propionibacterium acnes growth. Treatment is weight-based, usually dosed initially 0.5 mg/kg and increased to 1 mg/kg in 2 divided doses for 15-20 weeks. Once-daily dosing is not recommended. The dose may be adjusted to administer up to 2 mg/kg/day. The patients must be registered into the government-regulated iPledge program in order to receive the medication.

Previous
Next

Antibiotics, Other

Class Summary

Oral antibiotics are useful in inflammatory acne, and improvement is usually seen after several weeks of use. Antibiotic monotherapy is discouraged due to risk of development of resistant bacteria.

Females should be warned about the development of Candida albicans vaginitis. A rare complication of long-term oral antibiotic use is the development of gram-negative folliculitis. Tetracycline class antibiotics can cause sun sensitivity. Doxycycline is associated with GERD, and should be taken at least 30 minutes prior to sleep. Minocycline is rarely associated with a lupuslike syndrome, minocycline-induced hyperpigmentation, and pseudotumor cerebri.

Topical antibiotics are used in almost all acne patients. Monotherapy should be avoided to reduce risk of antibiotic resistance. Concurrent use of benzoyl peroxide eliminates the risk of development of resistance. Topical antibiotics are available as monotherapy or in fixed-dose combination products along with benzoyl peroxide or retinoids. Topical antibiotics used include clindamycin and erythromycin, though resistance to erythromycin favors the use of clindamycin.

Tetracycline

 

Tetracycline inhibits bacterial protein synthesis by binding with 30S and, possibly, 50S ribosomal subunit(s). Tetracycline has anti-inflammatory activity. Tetracycline may be administered at 250-500 mg PO bid.

Minocycline (Solodyn, Minocin)

 

Minocycline treats infections caused by susceptible gram-negative and gram-positive organisms, in addition to infections caused by susceptible Chlamydia, Rickettsia, and Mycoplasma species. The brand name Solodyn is an extended-release formulation indicated for acne and is prescribed as a weight-based 1-mg/kg dose per day. The minocycline dose should be lowered in patients with renal impairment.

Doxycycline (Doryx, Adoxa, Doxy 100, Vibramycin)

 

Doxycycline treats infections caused by susceptible gram-negative and gram-positive organisms. It inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Doxycycline may block dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest. The brand name 150-mg Doryx is enteric coated, to reduce adverse gastrointestinal effects.

Trimethoprim/sulfamethoxazole (Bactrim, Bactrim DS, Septra DS, Sulfatrim)

 

Trimethoprim/sulfamethoxazole is an antibiotic with activity against many gram-positive and gram-negative organisms. It inhibits bacterial growth by inhibiting the synthesis of dihydrofolic acid. It is available as 80 mg trimethoprim and 400 mg sulfamethoxazole or as 160 mg trimethoprim and 800 mg sulfamethoxazole (double strength).

Clindamycin (Cleocin)

 

Clindamycin is a lincosamide for the treatment of serious skin and soft tissue staphylococcal infections. It is also effective against aerobic and anaerobic streptococci (except enterococci). It inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Clindamycin is commonly used topically, but it can be given orally. Oral monotherapy administration should be avoided to reduce the risk of antibiotic resistance. It may administered at 75-300 mg/day in divided doses.

Clindamycin topical (ClindaGel, Cleocin-T, ClindaMax)

 

Topical clindamycin is a lincosamide for treatment of serious skin and soft tissue staphylococcal infections. It is also effective against aerobic and anaerobic streptococci (except enterococci). It inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. It is commonly used topically, but it can be given orally. Apply a thin film twice daily, except for the gel form, which is applied once daily.

Erythromycin topical (Akne-mycin, Erygel, Ery)

 

Topical erythromycin inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. It is commonly prescribed for acne as a topical gel in combination with benzoyl peroxide. Its use is limited because of resistant P acnes strains. Apply twice daily after washing the skin and drying it.

Daptomycin (Cubicin)

 

Daptomycin binds to bacterial membranes and causes rapid membrane potential depolarization, thereby inhibiting protein, DNA, and RNA synthesis, ultimately causing cell death. It is indicated for complicated skin and skin-structure infections caused by S aureus (including methicillin-resistant strains), S pyogenes, S agalactiae, S dysgalactiae, and E faecalis (vancomycin-susceptible strains only). Daptomycin has been used for the treatment of Propionibacterium osteomyelitis.

Previous
Next

Aldosterone Antagonists, Selective

Class Summary

Aldosterone antagonists may reduce free testosterone levels and compete with androgens binding at the sebaceous gland.

Spironolactone (Aldactone)

 

Spironolactone is an aldosterone antagonist that competes with testosterone and dihydrotestosterone binding at the receptor in the sebaceous gland. It also reduces free testosterone levels as more blood is bound by an increased quantity of SHBG. To treat acne in women, 25-200 mg once daily may be administered.

Previous
Next

Estrogens/Progestins

Class Summary

Hormonal therapies can be used in females with acne, especially those with premenstrual acne flares in whom other therapies have failed. Patients may also have signs of hyperandrogenism (eg, hirsutism, irregular menses, menstrual dysfunction). Serum androgen levels may or may not be elevated.

Available options include combination estrogen-progestin oral contraceptive pills, which suppress ovarian androgen production as well as androgen receptor blockers that block the effect of androgens peripherally at the sebaceous gland.

Ethinyl estradiol, drospirenone, and levomefolate (Beyaz)

 

Ethinyl estradiol, drospirenone, and levomefolate is a combination of estrogen and progestin that treats acne in adult women. It suppresses ovarian production of androgens.

Ethinyl estradiol and norethindrone (Estrostep Fe, Tilia Fe, Tri-Legest Fe, Femcon FE)

 

Ethinyl estradiol and norethindrone is a combination of estrogen and progestin that treats acne in adult women. It suppresses ovarian production of androgens.

Ethinyl estradiol and norgestimate (Ortho Tri-Cyclen, Tri-Estarylla, Tri-Previfem, Tri-Sprintec)

 

Ethinyl estradiol and norgestimate is a combination of estrogen and progestin treats acne in adult women. It suppresses ovarian production of androgens.

Ethinyl estradiol and drospirenone (Yaz, Zarah, Gianvi, Ocella, Yasmin)

 

Ethinyl estradiol and drospirenone is a combination of estrogen and progestin that treats acne in adult women. It suppresses ovarian production of androgens.

Previous
Next

Acne Products

Class Summary

Acne products are used for the treatment of mild to moderate acne vulgaris. These agents may have antibacterial and comedolytic properties. In severe cases, the agents may be used as an adjunct in therapeutic regimens.

Erythromycin and benzoyl peroxide (Benzamycin)

 

This combination agent contains erythromycin, which is a macrolide antibiotic, as well as benzoyl peroxide. Benzoyl peroxide, in addition to being an antibacterial agent, is a keratolytic and desquamative agent. With benzoyl peroxide, free-radical oxygen is released upon administration, oxidizing bacterial proteins in sebaceous follicles and decreasing the number of anaerobic, bacterial, and irritating free fatty acids. This combination has keratolytic and comedolytic effects. Erythromycin is indicated for infections caused by susceptible strains of microorganisms. The combination drug may be applied topically twice daily.

Clindamycin and tretinoin (Ziana, Veltin)

 

This combination agent contains the topical antibiotic clindamycin 1.2%, as well as tretinoin 0.025%. Clindamycin reduces P acnes levels and is an anti-inflammatory. Tretinoin normalizes differentiation of keratinocytes and is anti-inflammatory. Apply daily to affected areas.

Clindamycin and benzoyl peroxide (Acanya, Duac, BenzaClin)

 

This combination agent contains the topical antibiotic clindamycin as well as benzoyl peroxide. Clindamycin reduces P acnes levels and is anti-inflammatory. Benzoyl peroxide is antibacterial agent, comedolytic, and anti-inflammatory. Benzoyl peroxide reduces risk of development of bacterial resistance to clindamycin. Acanya gel contains 2.5% benzoyl peroxide and Duac CS and BenzaClin contain 5% benzoyl peroxide. Apply Acanya and Duac CS once daily. BenzaClin is applied twice daily.

Azelaic acid (Azelex, Finacea)

 

Azelaic acid has been shown to help reduce inflammation and may aid in the treatment of postinflammatory hyperpigmentation. Apply azelaic acid twice daily. Improvement may be seen within 4 weeks.

Benzoyl peroxide (BenzEFoam, PanOxyl, Neutrogena Clear Pore, Benzac AC Wash)

 

Benzoyl peroxide is an oxidizing agent that possesses antibacterial properties and is comedolytic. The antibacterial activity results from the release of active or free-radical oxygen that can oxidize bacterial proteins. Benzoyl peroxide is oxidized into benzoic acid with contact to the skin. It is available over the counter and by prescription.

Previous
 
Contributor Information and Disclosures
Author

Jaggi Rao, MD, FRCPC Clinical Professor of Medicine, Division of Dermatology and Cutaneous Sciences, Director of Dermatology Residency Program, University of Alberta Faculty of Medicine and Dentistry

Jaggi Rao, MD, FRCPC is a member of the following medical societies: American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, Canadian Medical Association, Pacific Dermatologic Association, Royal College of Physicians and Surgeons of Canada, Canadian Medical Protective Association, Canadian Dermatology Association

Disclosure: Nothing to disclose.

Coauthor(s)

Jennifer Chen University of Alberta Faculty of Medicine and Dentistry, Canada

Disclosure: Nothing to disclose.

Specialty Editor Board

David F Butler, MD Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: American Medical Association, Alpha Omega Alpha, Association of Military Dermatologists, American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Phi Beta Kappa

Disclosure: Nothing to disclose.

Jeffrey Meffert, MD Associate Clinical Professor of Dermatology, University of Texas School of Medicine at San Antonio

Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Joshua A Zeichner, MD Assistant Professor, Director of Cosmetic and Clinical Research, Mount Sinai School of Medicine; Chief of Dermatology, Institute for Family Health at North General

Joshua A Zeichner, MD is a member of the following medical societies: American Academy of Dermatology, National Psoriasis Foundation

Disclosure: Received consulting fee from Valeant for consulting; Received grant/research funds from Medicis for other; Received consulting fee from Galderma for consulting; Received consulting fee from Promius for consulting; Received consulting fee from Pharmaderm for consulting; Received consulting fee from Onset for consulting.

References
  1. Dawson AL, Dellavalle RP. Acne vulgaris. BMJ. 2013 May 8. 346:f2634. [Medline].

  2. Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol. 1999 Aug. 141(2):297-300. [Medline].

  3. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009 May. 60(5 Suppl):S1-50. [Medline].

  4. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol. 1999 Feb. 140(2):273-82. [Medline].

  5. Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008 Jan. 58(1):56-9. [Medline].

  6. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003 Jul. 121(1):20-7. [Medline].

  7. Norris JF, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol. 1988 May. 118(5):651-9. [Medline].

  8. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002 Aug 1. 169(3):1535-41. [Medline].

  9. Webster GF. Inflammatory acne represents hypersensitivity to Propionibacterium acnes. Dermatology. 1998. 196(1):80-1. [Medline].

  10. Pochi PE, Strauss JS. Sebaceous gland activity in black skin. Dermatol Clin. 1988 Jul. 6(3):349-51. [Medline].

  11. Lucky AW, Biro FM, Simbartl LA, Morrison JA, Sorg NW. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Pediatr. 1997 Jan. 130(1):30-9. [Medline].

  12. Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, et al. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol. 2006 Sep. 126(9):2002-9. [Medline].

  13. Smith TM, Cong Z, Gilliland KL, Clawson GA, Thiboutot DM. Insulin-like growth factor-1 induces lipid production in human SEB-1 sebocytes via sterol response element-binding protein-1. J Invest Dermatol. 2006 Jun. 126(6):1226-32. [Medline].

  14. Zouboulis CC, Böhm M. Neuroendocrine regulation of sebocytes -- a pathogenetic link between stress and acne. Exp Dermatol. 2004. 13 Suppl 4:31-5. [Medline].

  15. Smith RN, Mann NJ, Braue A, Makelainen H, Varigos GA. The effect of a high-protein, low glycemic-load diet versus a conventional, high glycemic-load diet on biochemical parameters associated with acne vulgaris: a randomized, investigator-masked, controlled trial. J Am Acad Dermatol. 2007 Aug. 57(2):247-56. [Medline].

  16. Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. J Clin Aesthet Dermatol. 2010 Apr. 3(4):24-38. [Medline]. [Full Text].

  17. Shaw JC, White LE. Persistent acne in adult women. Arch Dermatol. 2001 Sep. 137(9):1252-3. [Medline].

  18. [Guideline] Eichenfield LF, Krakowski AC, Piggott C, Del Rosso J, Baldwin H, Friedlander SF, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013 May. 131 Suppl 3:S163-86. [Medline].

  19. Kligman AM. Postadolescent acne in women. Cutis. 1991 Jul. 48(1):75-7. [Medline].

  20. Barnes LE, Levender MM, Fleischer AB Jr, Feldman SR. Quality of life measures for acne patients. Dermatol Clin. 2012 Apr. 30(2):293-300, ix. [Medline].

  21. Momin SB, Peterson A, Del Rosso JQ. A status report on drug-associated acne and acneiform eruptions. J Drugs Dermatol. 2010 Jun. 9(6):627-36. [Medline].

  22. Mango D, Ricci S, Manna P, Miggiano GA, Serra GB. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception. 1996 Mar. 53(3):163-70. [Medline].

  23. Basler RS. Acne mechanica in athletes. Cutis. 1992 Aug. 50(2):125-8. [Medline].

  24. [Guideline] Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 May. 74 (5):945-973.e33. [Medline].

  25. Cunliffe WJ, Holland DB, Jeremy A. Comedone formation: etiology, clinical presentation, and treatment. Clin Dermatol. 2004 Sep-Oct. 22(5):367-74. [Medline].

  26. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003 Jul. 49(1 Suppl):S1-37. [Medline].

  27. Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008. 9(6):369-81. [Medline].

  28. Zaenglein AL. Topical retinoids in the treatment of acne vulgaris. Semin Cutan Med Surg. 2008 Sep. 27(3):177-82. [Medline].

  29. Cunliffe WJ, Holland KT. The effect of benzoyl peroxide on acne. Acta Derm Venereol. 1981. 61(3):267-9. [Medline].

  30. Eady EA, Jones CE, Gardner KJ, Taylor JP, Cove JH, Cunliffe WJ. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br J Dermatol. 1993 May. 128(5):556-60. [Medline].

  31. Toossi P, Farshchian M, Malekzad F, Mohtasham N, Kimyai-Asadi A. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol. 2008 Dec. 7(12):1149-52. [Medline].

  32. Miller YW, Eady EA, Lacey RW, Cove JH, Joanes DN, Cunliffe WJ. Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother. 1996 Nov. 38(5):829-37. [Medline].

  33. Fanelli M, Kupperman E, Lautenbach E, Edelstein PH, Margolis DJ. Antibiotics, Acne, and Staphylococcus aureus Colonization. Arch Dermatol. 2011 Aug. 147(8):917-21. [Medline].

  34. Bottomley WW, Cunliffe WJ. Oral trimethoprim as a third-line antibiotic in the management of acne vulgaris. Dermatology. 1993. 187(3):193-6. [Medline].

  35. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol. 2000 Jan. 39(1):45-50. [Medline].

  36. Koulianos GT. Treatment of acne with oral contraceptives: criteria for pill selection. Cutis. 2000 Oct. 66(4):281-6. [Medline].

  37. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000 Sep. 43(3):498-502. [Medline].

  38. Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs. 1984 Jul. 28(1):6-37. [Medline].

  39. Lee JW, Yoo KH, Park KY, Han TY, Li K, Seo SJ, et al. Effectiveness of Conventional, Low-dose and Intermittent Oral Isotretinoin in the Treatment of Acne: A Randomized, Controlled Comparative study. Br J Dermatol. 2010 Nov 29. [Medline].

  40. White GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after the first course of isotretinoin. Arch Dermatol. 1998 Mar. 134(3):376-8. [Medline].

  41. Halvorsen JA, Stern RS, Dalgard F, Thoresen M, Bjertness E, Lien L. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol. 2011 Feb. 131(2):363-70. [Medline].

  42. Jacobs DG, Deutsch NL, Brewer M. Suicide, depression, and isotretinoin: is there a causal link?. J Am Acad Dermatol. 2001 Nov. 45(5):S168-75. [Medline].

  43. Bagatin E, dos Santos Guadanhim LR, Yarak S, Kamamoto CS, de Almeida FA. Dermabrasion for acne scars during treatment with oral isotretinoin. Dermatol Surg. 2010 Apr. 36(4):483-9. [Medline].

  44. Cunliffe WJ, Goulden V. Phototherapy and acne vulgaris. Br J Dermatol. 2000 May. 142(5):855-6. [Medline].

  45. Fulton JE Jr, Plewig G, Kligman AM. Effect of chocolate on acne vulgaris. JAMA. 1969 Dec 15. 210(11):2071-4. [Medline].

  46. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol. 1996 Aug. 132(8):934-9. [Medline].

  47. [Guideline] American Academy of Dermatology. Ten Things Physicians and Patients Should Question. Choosing Wisely. April 30, 2016. Available at http://www.choosingwisely.org/societies/american-academy-of-dermatology/. August 19, 2015;

  48. [Guideline] Asai Y, Baibergenova A, Dutil M, Humphrey S, Hull P, Lynde C, et al. Management of acne: Canadian clinical practice guideline. CMAJ. 2015 Nov 16. [Medline]. [Full Text].

  49. Harding A. Canadian dermatologists issue new acne treatment guidelines. Reuters Health Information. Available at http://www.medscape.com/viewarticle/854601. November 18, 2015; Accessed: December 11, 2015.

  50. FDA safety alert. Over-The-Counter Topical Acne Products: Drug Safety Communication - Rare But Serious Hypersensitivity Reactions. U.S. Food and Drug Administration. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm402722.htm. Accessed: June 30, 2014.

 
Previous
Next
 
Acne, grade I; multiple open comedones.
Acne, grade II; closed comedones.
Acne, grade III; papulopustules.
Acne, grade IV; multiple open comedones, closed comedones, and papulopustules, plus cysts.
Acne with reactive hyperpigmentation; before treatment.
Acne with reactive hyperpigmentation; after treatment.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.